TB-500 Side Effects: What the Research Actually Shows

TB-500 is one of the two most talked-about repair peptides in the world, usually mentioned in the same breath as BPC-157, and “TB-500 side effects” is one of the most searched questions about it. As with BPC-157, the online answers swing between “completely safe” and alarming warnings, usually without evidence. The real picture is more nuanced, and in one respect more reassuring: the natural protein TB-500 is based on, thymosin beta-4, has actually been through formal clinical trials, which is more than most research peptides can say. But there are also genuine open questions, including one about its role in cell growth that researchers take seriously.

This guide sets out what TB-500 is, what the human and animal research has found about safety, what questions remain unanswered and why product identity is a particular issue for this compound. It is an educational overview of research findings, not medical advice. Crown Peptides supplies TB-500 for laboratory research use only.

The Short Answer

Thymosin beta-4, the natural protein behind TB-500, has been tested in several formal clinical trials, including trials of an eye drop formulation for dry eye, where no adverse events were reported, and early-phase trials of other formulations. Those trials suggest it was well tolerated in the settings studied. However, controlled human safety data on the research product sold as TB-500 are essentially absent, there are no long-term human studies, and research linking thymosin beta-4 to cancer cell migration has raised a theoretical question that has not been resolved.

What TB-500 Is, and Why That Matters for Safety

Thymosin beta-4

Thymosin beta-4 is a 43-amino-acid protein found in almost every cell in the body, and at especially high levels in blood platelets and white blood cells. It was first isolated from the thymus by Allan Goldstein’s group, which is how it got its name. Its main job inside cells is to bind actin, the protein scaffolding cells use to change shape and move, holding it in reserve until it is needed.

The repair connection

Research has linked thymosin beta-4 to wound healing, blood vessel growth and reduced inflammation. A 2010 review in the Annals of the New York Academy of Sciences described its roles in tissue repair and regeneration (PMID: 20179146), and a 2012 review described it as a multi-functional regenerative peptide that promotes cell migration, reduces inflammation and reduces scarring in research models (PMID: 22074294).

The naming problem

“TB-500” is not a scientific name. It is a trade name used in the research market, and it has been used for different things: sometimes the full 43-amino-acid thymosin beta-4 or a close synthetic version of it, and sometimes a much shorter synthetic fragment corresponding to its actin-binding region. That matters for safety, because clinical trial data on full thymosin beta-4 do not automatically apply to a fragment, and vice versa. Knowing exactly what a product contains, confirmed by mass spectrometry, is the first step in understanding its profile. Our TB-500 guide explains this in more detail.

A Short History of Thymosin Beta-4

In the 1960s, Allan Goldstein and Abraham White began extracting hormone-like factors from the thymus, the organ where immune T cells mature. They called the extract thymosin fraction 5, and over the following decade researchers separated it into individual peptides, named thymosins alpha and beta after their chemical properties. Thymosin beta-4 was characterised in the early 1980s. At first it was thought to be a thymic hormone, but researchers soon found it in almost every cell, far from the thymus, and discovered that its main job was binding actin. From the 1990s onwards, research revealed its roles in wound healing and blood vessel growth, leading to clinical development programmes and, eventually, the research product known as TB-500.

Why Thymosin Beta-4 Is Everywhere in the Body

Thymosin beta-4 is one of the most abundant small proteins in human cells, and it is particularly concentrated in blood platelets. When a tissue is injured, platelets gather at the site and release their contents, including large amounts of thymosin beta-4. This natural release at wounds is one reason researchers believe it plays a part in the body’s own repair process. It also means the body is well used to having thymosin beta-4 around, which is part of why the clinical trials found it well tolerated. But the amounts and patterns of exposure from outside supply can differ greatly from natural release, which is why natural presence does not settle the safety question on its own.

What the Clinical Trials of Thymosin Beta-4 Found

Eye drops for dry eye

The most detailed human safety data come from trials of a thymosin beta-4 eye drop solution. In a 2015 phase 2 randomised, placebo-controlled trial in Clinical Ophthalmology, Sosne and colleagues tested a 0.1% thymosin beta-4 eye solution in people with dry eye, using a controlled environment designed to provoke symptoms (PMID: 26056426, PMC4445951). The trial did not meet its two primary endpoints, but showed improvements in several secondary measures, and no adverse events were observed. A separate 2015 phase 2 trial in Cornea reported that thymosin beta-4 significantly improved signs and symptoms of severe dry eye (PMID: 25826322).

Other clinical programmes

Thymosin beta-4 has also been developed in other formulations, including for skin wounds and for heart conditions, with early-phase studies reported to show good tolerability. These programmes were run by a development company and progressed to phase 2 in some areas.

What these trials can and cannot tell us

These are genuine controlled trials, which is valuable. But eye drops deliver a small amount of protein to one surface of the body, very different from how the research product is discussed online. The trials were also relatively small and short. They tell us that thymosin beta-4 was well tolerated in those specific settings, not that any product labelled TB-500 is safe in any form.

What Animal Research Shows

Thymosin beta-4 has been studied in many animal models of wound healing, heart injury, eye injury, hair growth and brain injury, generally without reports of obvious toxicity. Like much repair research, these studies were designed mainly to test healing rather than to hunt systematically for harm, so they are not a substitute for formal toxicology.

Why Eye Drop Trials Tell Only Part of the Story

The dry eye trials are the most rigorous human safety data for thymosin beta-4, and they are genuinely reassuring within their scope. But it is worth understanding their limits. Eye drops deliver a small amount of protein to the surface of the eye, where very little is likely to reach the rest of the body. The trials lasted weeks rather than years and involved relatively small numbers of participants. And their purpose was to test effects on the eye, so they were not designed to detect effects elsewhere in the body. Research interest in TB-500, by contrast, often concerns systemic effects on tissues such as tendons and muscle, a very different kind of exposure. Extending the eye drop findings to that context would go beyond what the data can support.

The Open Question: Cell Migration and Cancer

Why the question arises

Thymosin beta-4’s central talent is helping cells move. That is exactly what makes it interesting for wound healing, where cells must migrate into damaged tissue. But cell migration is also how cancer cells invade and spread.

What the research has found

Research has found thymosin beta-4 at high levels in some tumours. A 2012 study in Cancer Biology and Therapy found it concentrated at the invasion front of colorectal cancers, in tumour cells undergoing the changes associated with invasion (PMID: 22233609). A 2021 study in Molecular Carcinogenesis identified the gene for thymosin beta-4 as promoting metastasis in a model of diffuse-type gastric cancer (PMID: 34081824).

What this does and does not mean

These studies show that thymosin beta-4 is involved in the behaviour of some cancer cells. They do not show that supplying thymosin beta-4 causes cancer, and much of the research concerns the cancer cells’ own production of it. But they raise a reasonable theoretical question about whether extra thymosin beta-4 could, in some circumstances, support the spread of existing tumours, a question that has not been answered by long-term human research. Researchers take this question seriously, and it is one of the main reasons caution is warranted.

Other Unanswered Questions

Long-term effects

There are no long-term human studies of TB-500 or thymosin beta-4 given systemically.

Immune reactions

Any protein or peptide can, in principle, trigger an immune response, particularly if impure. This has not been systematically studied for research products.

Interactions

Interactions with medicines have not been studied.

Specific groups

There are no data on pregnancy, children or people with existing medical conditions.

Claims You May See Online, Examined

Online discussions of TB-500 often include anecdotal reports of effects such as tiredness, headaches or temporary changes in how people feel. Without controlled studies using verified material, it is impossible to know whether such effects are caused by thymosin beta-4, by impurities, by a different molecule sold under the same name or by chance. Given the naming problem described above, the product question is especially important for TB-500: two people describing their experiences may not even have been using the same compound. Only properly designed research can separate real effects from coincidence and product variation. These informal reports are not research data, and Crown Peptides does not condone personal or human use of research compounds.

Inflammation: A Two-Sided Effect

Thymosin beta-4 has been reported in research to reduce inflammation in several models, which is part of its appeal in repair research. But inflammation is not always harmful: it is an essential early stage of healing and a key defence against infection. A compound that dampens inflammation could, in principle, affect how the body responds to infection or other challenges. There is no evidence that thymosin beta-4 causes problems of this kind, but it is one reason researchers value studies that measure immune function alongside healing, rather than assuming that less inflammation is always better.

What Regulators and Sport Say

Thymosin beta-4 and TB-500 are prohibited in sport under the World Anti-Doping Agency’s rules on peptide hormones, growth factors and related substances, and several athletes have been sanctioned for it. In the UK, TB-500 is not a controlled drug, but it is not a licensed medicine and is supplied for research only. In July 2026, a US FDA advisory committee voted to recommend adding TB-500 to the list of substances compounding pharmacies may use, a recommendation that requires further FDA action. Our article on the FDA advisory panel vote explains what that means.

Full-Length Protein vs Fragment: Why It Matters

The distinction between full-length thymosin beta-4 and short fragments is not a technicality. The full protein has several functional regions: the actin-binding region, a region at the start of the chain that can be released as the small peptide Ac-SDKP, and others. A fragment containing only the actin-binding region may reproduce some effects of the full protein but not others, and may behave differently in the body, including in how long it lasts and where it goes. That means safety and effect data from one cannot be assumed to apply to the other. For researchers, recording exactly which molecule was used is essential for interpreting results and comparing studies.

Reading TB-500 Research Critically

Which molecule was studied?

Check whether a study used full-length thymosin beta-4, a fragment or a product simply labelled TB-500.

What kind of study?

Cell studies, animal studies and clinical trials carry very different weight.

What formulation?

Eye drops, skin gels and systemic forms expose the body very differently.

How long?

Short studies cannot reveal long-term effects.

Was there a control group?

Without one, effects cannot be separated from chance or natural recovery.

Why Product Identity Is Especially Important for TB-500

Because the name TB-500 has been used for different molecules, and because the full protein is 43 amino acids long and demanding to make, identity verification is especially important. A product might contain full-length thymosin beta-4, a short fragment, a partially made chain or something else entirely. Only mass spectrometry, which measures the exact molecular mass, can confirm which. Studies of unregulated peptide products have found very low purity and contamination (PMID: 30029448). Every batch supplied by Crown Peptides comes with a batch-specific certificate of analysis showing HPLC purity and mass spectrometry identity, with lot numbers matching vial labels. Published certificates are on our Lab Reports page, and our guide how to tell if peptides are real explains verification.

Why “Natural” Does Not Settle the Question

A common argument is that TB-500 must be safe because thymosin beta-4 is a natural protein found in almost every cell. The argument has some basis: the body is well used to thymosin beta-4, and the clinical trials found it well tolerated. But natural presence does not guarantee safety at different amounts, in different places or for longer periods. The body releases thymosin beta-4 in controlled bursts at specific sites, such as wounds, and regulates it carefully. Supplying it from outside, possibly as a fragment rather than the full protein, is a different situation. And the very property that makes it natural and useful, promoting cell migration, is the source of the open question about cancer. The fair conclusion is that its natural origin is reassuring in some respects but not decisive.

What the Research Community Thinks

Researchers who study thymosin beta-4 generally regard it as a genuinely interesting regenerative molecule with a stronger evidence base than many research peptides, thanks to its clinical trial history. At the same time, many emphasise the need to understand its role in cancer biology more fully, and to distinguish carefully between the well-characterised protein used in clinical programmes and the variable products sold as TB-500. That balanced view, real promise combined with specific, unresolved questions, reflects the current state of the evidence.

TB-500 vs BPC-157: How Their Evidence Compares

The two peptides are often discussed together, but their safety evidence differs. BPC-157 has a very large animal literature but almost no controlled human data, just a two-person pilot and small uncontrolled reports, as explained in BPC-157 side effects. Thymosin beta-4 has a smaller but still substantial animal literature and has been through formal phase 2 clinical trials in some formulations. Both share a theoretical question about growth: BPC-157 through its effects on blood vessel growth, thymosin beta-4 through cell migration. Neither has long-term human data. See BPC-157 vs TB-500.

How Long-Term Safety Would Be Established

Establishing the long-term safety of systemic thymosin beta-4 would require formal toxicology, including longer-term animal studies with attention to tumour development, followed by human trials of increasing size and length using verified material, with systematic recording of all adverse events and long-term follow-up. The clinical programmes run so far have covered parts of this path for specific formulations. The research product has not been through it. Until it has, statements about TB-500’s long-term safety cannot be made with confidence.

What Recent Regulatory Attention Means

The July 2026 FDA advisory committee vote on TB-500 reflects growing regulatory interest in this class of peptides. It is important to understand what the vote was and was not. It was a recommendation about whether US compounding pharmacies may use the substance, not an approval of TB-500 as a medicine and not a finding that it is safe for any particular use. It requires further FDA action before anything changes in the United States, and it has no bearing on its status in the UK, where it remains a research material.

Designing Research With TB-500

Know what you are using

Confirm by mass spectrometry whether the material is full-length thymosin beta-4 or a fragment, and report it clearly.

Measure beyond healing

Studies designed to test repair can add measures of cell proliferation, inflammation and organ function, building a fuller picture of effects.

Consider the growth question

Where relevant, studies can include markers of cell migration and proliferation in tissues beyond the target, helping address the open question directly.

The Technical Breakdown: Actin, Migration and Repair

Actin sequestration

Thymosin beta-4 binds single actin molecules, called G-actin, preventing them from joining into filaments. When a cell needs to move, actin is released to build filaments that push the cell’s leading edge forward.

The LKKTETQ motif

A short sequence within thymosin beta-4, LKKTETQ, is central to its actin binding, and synthetic fragments based on this region have been sold under the TB-500 name.

Beyond actin

Thymosin beta-4 has also been linked to effects on inflammation, blood vessel growth and cell survival, some possibly through its breakdown product, Ac-SDKP.

Why migration cuts both ways

The same machinery that lets repair cells move into a wound lets cancer cells move into surrounding tissue, which is the root of the theoretical concern.

Using TB-500 Responsibly in the Laboratory

For laboratory research, TB-500 should be stored as a freeze-dried powder, cold, dry and away from light, and reconstituted solutions kept refrigerated and used within a sensible period. Because it is a relatively large peptide, gentle reconstitution, swirling rather than shaking, helps avoid damaging it. Using a single verified batch throughout a study removes one of the most common hidden sources of variation. Our guides to peptide reconstitution, how long peptides last and the peptide calculator cover the practical side, and Bacteriostatic Water is available alongside.

Related Compounds and Reading

TB-500 is combined with BPC-157 in the Wolverine Stack (BPC-157 + TB-500 Blend) and appears in GLOW and KLOW. Related compounds include BPC-157 and Thymosin Alpha-1. Read are peptides safe and Thymosin Alpha-1 vs TB-500, and browse the tissue biology research peptides category.

TB-500 Side Effects: Questions, Answered

Does TB-500 have any known side effects?

Its side effect profile as a research product is not established. Thymosin beta-4 was well tolerated in clinical trials of specific formulations, such as eye drops, but there are no long-term human data.

Is TB-500 the same as thymosin beta-4?

Not always. The name has been used for full-length thymosin beta-4 and for short synthetic fragments, which is why mass spectrometry identity testing matters.

Can TB-500 cause or promote cancer?

There is no evidence that it does, but research linking thymosin beta-4 to cancer cell migration has raised a theoretical question about existing tumours that has not been resolved.

Has thymosin beta-4 ever been tested in people?

Yes, in formal clinical trials, including phase 2 trials of an eye drop for dry eye, where no adverse events were reported in one trial.

Why is thymosin beta-4 found in platelets?

Platelets store and release it at injury sites, which is one reason researchers believe it plays a part in the body’s natural repair process.

Were there side effects in the dry eye trials?

In the 2015 Clinical Ophthalmology trial, no adverse events were observed. The trials were short and involved eye drops, so they do not describe systemic exposure.

How can researchers know what their TB-500 contains?

By using material with a batch-specific certificate of analysis showing mass spectrometry identity, which distinguishes full-length thymosin beta-4 from fragments.

Is TB-500 safer than BPC-157?

Neither can be called safe in a general sense. Thymosin beta-4 has more formal clinical trial data in specific formulations, while BPC-157 has a larger animal literature but almost no controlled human data. Both share open questions about growth and have no long-term human data.

Does TB-500 affect the immune system?

Thymosin beta-4 has been reported in research to reduce inflammation in several models. Its broader effects on immune function in people have not been studied systematically.

Where can I read the studies?

Every study in this guide is linked to its PubMed record, where the abstract and often the full paper can be read.

What exactly is Ac-SDKP?

A small peptide released from the start of thymosin beta-4, which has been linked in research to some of its anti-inflammatory and blood vessel effects.

Is TB-500 an approved medicine?

No. It is not a licensed medicine in the UK or elsewhere. The 2026 FDA advisory vote was a recommendation about compounding pharmacy access, not an approval.

Is TB-500 banned in competitive sport?

Yes. It is prohibited under the World Anti-Doping Agency’s rules.

More Evidence Than Most, Still Not Enough

TB-500 sits in an unusual place among research peptides. The natural protein it is based on has been through formal clinical trials and was well tolerated in them, a genuine point in its favour. But those trials involved specific formulations, the research product’s identity varies, long-term data do not exist, and its central role in cell migration raises a question about cancer that researchers cannot yet answer. The honest summary is cautious: better studied than many research peptides, but not yet understood well enough to call its side effects known, especially over the long term and in the systemic forms most often discussed.

For laboratory research, start with verified material. Explore TB-500 from Crown Peptides, every batch HPLC and mass spectrometry verified and dispatched from the UK.